CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Nasal swabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug819 Taste and olfactory function evaluation Wiki 0.71
drug745 Serum testing Wiki 0.71

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Study of the Pathogenesis of Olfactory Disorders in COVID-19

This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.

NCT04366934 Coronavirus Infection Severe Acute Respiratory Syndrome Sars-CoV2 Other: Nasal swab Other: Taste and olfactory function evaluation
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Ratio of olfactory sensory cells in the nasal cytological sample

Measure: Molecular and cellular defects in olfactory epithelium

Time: 30 months

Secondary Outcomes

Description: Multiple measurements will be analyzed to characterize the immune and inflamatory status of the olfactory mucosa (presence of infiltrated immune cells, activation state of the immune cells in the epithelium, cytokine and interleukin level)

Measure: Biological mechanisms involved in the pathogenesis of the disease

Time: 30 months

Description: Demographic variables (sex, age, blood type), risk factors (tobacco, overweight, diabetes, rhinosinusitis disease, respiratory allergy)

Measure: Epidemiological characteristics

Time: 30 months

Description: Self-questionnaire taste and smell survey (TTS)

Measure: Olfactory and taste dysfunction

Time: 30 months

Description: Visual analogue scale (VAS) (units from 0 normal perception to 100 no perception)

Measure: Olfactory and taste dysfunction

Time: 30 months

2 Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers

The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in symptomatic and asymptomatic HCWs over time and 3) to improve the assessment of the immune response and its protective effect as well as the assessment of infectivity of affected HCWs and 4) to evaluate the value and significance of antibody formation and serological antibody tests and 5) to be able to evaluate possible future preventive and / or therapeutic approaches against SARS-CoV-2

NCT04370119 SARS-Cov-2 Diagnostic Test: Nasal swab Diagnostic Test: Serum testing
MeSH:Infection

Primary Outcomes

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 1 year

Secondary Outcomes

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 1 year

Other Outcomes

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 2 years

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 3 years

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 4 years

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 5 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 2 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 3 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 4 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 5 years


No related HPO nodes (Using clinical trials)